TRPV2 and melanoma: Additionally, a similar “anti‐migratory” effect was obtained on WM266.4 cells treated with Tranilast, a pharmacological inhibitor of TRPV2 (Appendix Fig S3A), reinforcing the crucial role of TRPV2‐dependent Ca2+ entry in the migration and invasion potentials of melanoma cells.